

aerosolized composition comprising:

- (i) a dose of non-encapsulated cyclosporine in an amount effective to prevent graft rejection;
- (ii) and a propellant.

20. (amended) A method for prevention of graft rejection in a lung transplant recipient comprising administering to the recipient directly following transplantation an aerosolized composition comprising:

- (i) a dose of non-encapsulated cyclosporine in an amount effective to prevent graft rejection;
- (ii) a dry powder; and
- (iii) a propellant.


21. (amended) A method for prevention of graft rejection in a lung transplant recipient comprising administering to the recipient directly following transplantation an aerosolized composition comprising :

- (i) a dose of non-encapsulated cyclosporine in an amount effective to prevent graft rejection;
- (ii) an organic solvent; and
- (iii) a propellant.

25. (amended) A method for ameliorating pulmonary inflammation in a subject comprising administering to the subject an aerosolized composition comprising :

- (i) a dose of non-encapsulated cyclosporine in an amount effective to inhibit or ameliorate pulmonary inflammation; and
- (ii) a propellant.

26. (amended) A method for ameliorating pulmonary inflammation in a subject comprising administering to the subject an aerosolized composition comprising :

- 
- (i) a dose of non-encapsulated cyclosporine in an amount effective to inhibit or ameliorate pulmonary inflammation;
 - (ii) a dry powder; and
 - (iii) a propellant.

27. (Amended) A method for ameliorating pulmonary inflammation in a subject comprising administering to the subject an aerosolized composition comprising :

- (i) a dose of non-encapsulated cyclosporine effective to inhibit or ameliorate pulmonary inflammation;
- (ii) an organic solvent; and
- (iii) a propellant.

30. (amended) A method for prevention of graft rejection in a non-lung transplant

recipient comprising administering to the non-lung transplant recipient an aerosolized composition comprising :

- (i) a dose of non-encapsulated cyclosporine in an amount effective to prevent graft rejection;
- (ii) and a propellant.

31. (amended) A method for prevention of graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient an aerosolized composition comprising :

- (i) a dose of non-encapsulated cyclosporine in an amount effective to prevent graft rejection;
- (ii) a dry powder; and
- (iii) and a propellant.

32. (amended) A method for prevention of graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient an aerosolized composition comprising:

- (i) a dose of non-encapsulated cyclosporine in an amount effective to prevent graft rejection;
- (ii) an organic solvent; and
- (ii) and a propellant.

33. (amended) A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject comprising administering to the non-lung transplant recipient an aerosolized composition comprising:

- B3
cont
- (i) a dose of non-encapsulated cyclosporine in an amount effective to inhibit the immune response associated with a T-cell mediated immune disorder; and
 - (ii) a propellant.
-

36. (amended) A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject comprising administering to the non-lung transplant recipient an aerosolized composition comprising:

- B4
- (i) a dose of non-encapsulated cyclosporine in an amount effective to inhibit the immune response associated with a T-cell mediated immune disorder;
 - (ii) a dry powder; and
 - (iii) a propellant.

37. (amended) A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject comprising administering to the non-lung transplant recipient an aerosolized composition comprising:

- (i) a dose of non-encapsulated cyclosporine in an amount effective to inhibit the immune response associated with a T-cell mediated immune disorder;
- (ii) an organic solvent; and
- (iii) a propellant.

38. (amended) An aerosolized composition consisting essentially of:

- (i) non-encapsulated cyclosporine in a dose effective to reduce pulmonary inflammation in subjects having pulmonary disorders; and
- (ii) a propellant.

B4
ant

39. (amended) An aerosolized composition consisting essentially of :

- (i) non-encapsulated cyclosporine in a dose effective to reduce pulmonary inflammation in subjects having pulmonary disorders;
- (ii) a dry powder; and
- (iii) a propellant.

40. (amended) An aerosolized composition consisting essentially of :

- (i) non-encapsulated cyclosporine in doses effective to reduce

B4
cont

pulmonary inflammation in subjects having pulmonary disorders;

- (ii) an organic solvent; and
- (ii) a propellant.

44. (amended) An aerosolized composition consisting essentially of :

- (i) non-encapsulated cyclosporine in doses effective to prevent development of an immune response that would lead to graft rejection in a transplant recipient; and
- (ii) a propellant.

B5

45. (amended) An aerosolized composition consisting essentially of :

- (i) nonencapsulated cyclosporine in a dose sufficient to prevent development of an immune response that would lead to graft rejection in a transplant recipient;
- (ii) a dry powder; and
- (iii) a propellant.

Rule
124

48 46. (New) An aerosolized composition consisting essentially of :

- (i) non-encapsulated cyclosporine in a dose sufficient to prevent development of an immune response that would lead to graft rejection in a transplant recipient;

B4